Evidence map›Paper›PMID 31123690›Full record

ArticleOpen forum infectious diseases2019

INSTI-Based Triple Regimens in Treatment-Naïve HIV-Infected Patients Are Associated With HIV-RNA Viral Load Suppression at Ultralow Levels.

Sidonie Lambert-Niclot, Anders Boyd, Djeneba Fofana, Nadia Valin, Marc Wirden, Jean-Luc Meynard, Romain Palich, Rachid Agher, Marc-Antoine Valantin, Vincent Calvez and 4 more

Abstract read
In one paragraph

Article in Open forum infectious diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Sidonie Lambert-NiclotSorbonne Université, Paris, France.ORCID 0000-0002-3378-250X
Anders BoydINSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Paris, France.
Djeneba FofanaINSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Paris, France.
Nadia ValinAP-HP, Hôpital Saint-Antoine, Département de Maladies Infectieuses, Paris, France.
Marc WirdenINSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Paris, France.
Jean-Luc MeynardAP-HP, Hôpital Saint-Antoine, Département de Maladies Infectieuses, Paris, France.
Romain PalichSorbonne Université, Paris, France.
Rachid AgherAP-HP, Hôpital Pitié Salpêtrière, Département de Maladies Infectieuses, Paris, France.
Marc-Antoine ValantinSorbonne Université, Paris, France.
Vincent CalvezSorbonne Université, Paris, France.
Christine KatlamaSorbonne Université, Paris, France.
Pierre-Marie GirardSorbonne Université, Paris, France.
Anne-Geneviève MarcelinSorbonne Université, Paris, France.
Laurence Morand-JoubertSorbonne Université, Paris, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDuring antiretroviral therapy (ART), HIV-1-infected patients may present with ultralow (UL) HIV-RNA viral loads (VLs) below quantification levels of current assays. Reasons for UL-VL detection and its relation to virological rebound (VR) are unclear.

methodsHIV-1-infected, ART-naïve patients followed at 2 university hospitals were included. All participants had an HIV-RNA >200 copies/mL at ART initiation and achieved a VL <50 copies/mL during ART. UL-VL was determined by the presence/absence of polymerase chain reaction signal detected using a commercially available assay (COBAS, TaqMan, Roche). Random-effects Poisson regression was used for assessing determinants of UL-VL not detected overtime and conditional risk set analysis for VR (1 VL > 200 copies/mL or 2 VL > 50 copies/mL) while accounting for frequency of VL measurements.

resultsBetween 2009 and 2013, 717 patients initiated ART containing 2 nucleos(-t)ide reverse transcriptase inhibitors (NRTIs) plus a non-NRTI (29.4%), a protease inhibitor (58.4%), or an integrase-strand transfer inhibitor (INSTI; 12.1%). During a median (interquartile range) 3.4 (2.3-4.6) years, 676 (94.3%) patients achieved UL-VL not detected. In multivariable analysis, UL-VL not detected overtime was associated with younger age (

conclusionsVL suppression at an ultralow level is associated with INSTI-class ART initiation. Extensive VL suppression below ultralow detection could improve immune reconstitution.

Indexed as

HIVinitiation antiretroviral therapyintegrase inhibitorresidual viremia

Identifiers

PMID31123690
PMCPMC6524833

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.